Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06365749
Other study ID # TJ-IRB20221228
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date April 23, 2024
Est. completion date November 23, 2026

Study information

Verified date April 2024
Source Tongji Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Congenital hearing loss, as well as hearing loss present at birth, is one of the most common chronic conditions in children, with a prevalence of permanent bilateral hearing loss of 2.83 per 1000 children of primary school age, which is mainly caused by genetic factors. The goal of this observational study is to learn about novel causative genes in infants with hearing loss in the Chinese population. The main problem it aims to deal with are: - to present the genetic characteristics of the infant with hearing loss in the Chinese population - to build up a prognostic model base on diverse data. Participants will be asked to receive audiological tests and collection of the peripheral blood sample.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 50
Est. completion date November 23, 2026
Est. primary completion date November 23, 2026
Accepts healthy volunteers No
Gender All
Age group N/A to 6 Months
Eligibility Inclusion Criteria: - Age up to 6 months - Fail in the neonatal hearing screening programs, including oto-acoustic emissions and automated auditory brain stem response - Promise to complete the tests required at baseline and follow-ups by the legal representative - Informed consent by the legal representative Exclusion Criteria: - Congenital infections related to acquired or congenital hearing loss, including rubella virus, cytomegalovirus, herpes simplex virus, rubella virus, toxoplasma gondii and treponema pallidum infections - Other explicit otologic conditions which could induce hearing loss, including cerumen, otitis media, congenital middle ear abnormalities, microtia and external ear abnormalities - A drug with ototoxicity usage during pregnancy - Other severe congenital anomalies

Study Design


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Dan Bing

Outcome

Type Measure Description Time frame Safety issue
Primary Whole exome sequencing data DNA of neonate extracted from blood sample by heel prick or collection of cord blood will be perform whole exome sequencing to present genetic features. By sequencing all protein-coding regions, WES uncovers mutations that can inform diagnostic, therapeutic, and preventive strategies. Key outcome measures from WES include the detection of single nucleotide polymorphisms, insertions, deletions, and structural variants. These outcomes are critical for diagnosing genetic disorders, personalizing treatments, and assessing disease risk. The analysis involves aligning reads to a reference genome, calling variants, and interpreting their clinical significance. WES data thus serves as a cornerstone in genetic research and personalized medicine, enabling a deeper understanding of the genetic underpinnings of diseases and tailoring healthcare approaches to individual genetic profiles. Baseline
Secondary TEOAE-based otoacoustic emissions test outcome measure In analyzing Transient Evoked Otoacoustic Emissions (TEOAE), key factors include response reproducibility, which indicates consistent cochlear responses, and signal-to-noise ratio (SNR), where a value above 3 dB suggests clear cochlear emissions against background noise. The Response Spectrum provides a frequency-specific look at cochlear performance, essential for identifying potential hearing issues. A 'Pass' in the TEOAE test denotes normal cochlear function, while a 'Refer' indicates the need for further hearing evaluations. Baseline
Secondary Auditory brainstem response testing In auditory brainstem response (ABR) testing, waveform reproducibility and waveform latency, especially of Wave V, are key. High reproducibility indicates reliable signal transmission, suggesting a healthy auditory system. Appropriate latency for Wave V indicates efficient signal processing. Frequency-Specific Responses highlight the brainstem's reaction across different sound frequencies, aiding in identifying potential issues. 'Normal' ABR results reflect functional auditory pathways, while 'Abnormal' ones prompt further investigation. Baseline
Secondary Acoustic impedance Acoustic impedance, a critical parameter in sound wave dynamics, quantifies a medium's opposition to sound propagation, expressed as the ratio of acoustic pressure to particle velocity. This parameter is shaped by the medium's density and the speed of sound through it, pivotal for understanding sound behavior in various environments. In audiology, specifically in tympanometry, impedance measurements diagnose middle ear conditions by assessing how sound waves are absorbed or reflected, revealing conditions like effusion or tympanic membrane perforations. The results are typically classified into Jerger types, which categorize middle ear function based on the impedance curve's shape and peak characteristics, providing a detailed insight into middle ear health. High impedance may indicate obstructions or stiffness in the middle ear, while low impedance could suggest perforations or discontinuities. Baseline
Secondary Audiogram Pure-tone threshold testing is a cornerstone of audiological assessment, used to determine the softest level at which an individual can hear sounds of specific frequencies. During the test, pure tones of various frequencies are presented through headphones or earphones to one ear at a time, or through a speaker for bone conduction testing. The process begins at an audible level, gradually decreasing until the sound is no longer heard, then slightly increasing until it is heard again. This method helps identify the threshold, or the lowest level at which a sound is perceived 50% of the time for each frequency tested, typically ranging from low (250 Hz) to high (8000 Hz) frequencies. 4 years follow up
See also
  Status Clinical Trial Phase
Completed NCT00400413 - Neuroanatomy of Reading in Congenital Deafness. N/A
Recruiting NCT05402813 - Natural History in Children up to 10 Years With Moderate to Profound Hearing Loss Due to Mutations in GJB2 / OTOF Genes
Completed NCT03319524 - Clinical and Genetic Testing of Patients With Usher Syndrome
Completed NCT00106743 - Natural History and Genetic Studies of Usher Syndrome
Terminated NCT03866850 - Degenerative Consequences of Congenital Deafness
Not yet recruiting NCT06370351 - A Phase I/II Clinical Trial With SENS-501 in Children Suffering From Severe to Profound Hearing Loss Due to Otoferlin (OTOF) Mutations Phase 1/Phase 2
Not yet recruiting NCT04350619 - NGS Assessment of Congenitally Deafned Children and Neonatal Deafness Screnning